ZS Discovery
We help clients reinvent pharma discovery, elucidate disease biology, innovate novel therapeutics and accelerate drug development to create breakthrough science and increase the probability of R&D success and patient outcomes.
ZS Discovery
We help clients reinvent pharma discovery, elucidate disease biology, innovate novel therapeutics and accelerate drug development to create breakthrough science and increase the probability of R&D success and patient outcomes.
R&D Innovation
The future of medicine depends on data.
WHAT WE DO
Challenges we solve
We’re passionate about accelerating transformation in research and early development so clients can build capabilities in programmable biology across therapeutic modalities. Our integrated approach is multidisciplinary and led by science.
WHAT WE DO
Challenges we solve
We’re passionate about accelerating transformation in research and early development so clients can build capabilities in programmable biology across therapeutic modalities. Our integrated approach is multidisciplinary and led by science.
Creating better breakthrough science
Creating better breakthrough science
We help teams elucidate and better understand disease biology, improve patient stratification through molecular and phenotypical insights and the leverage of patient clinical insights to optimize modality choice and identify novel targets, biomarkers and drug candidates.
Increasing the probability of success
Increasing the probability of success
We work with clients to reduce risk, scale the probability of scientific regulatory success and reimbursement success through data, AI, analytics and technology-driven platforms.
Transforming R&D organizations
Transforming R&D organizations
We help organizations become more agile, overcome inertia, break silos and optimize the right talent pool to promote disruptive innovation, foster organization-wide transformation and drive nonlinear drug development.
ZS Revelen
Uncover protein functions and disease hypotheses with ZS Revelen
ZS Revelen
Uncover protein functions and disease hypotheses with ZS Revelen
- A
- B
HOW WE DO IT
ZS’s approach
Our talent pool of molecular natives has scientific expertise across disciplines, including therapeutic, molecular science, bioinformatics and data science. Their expertise, combined with AI and ML technologies, drives breakthrough science.
HOW WE DO IT
ZS’s approach
Our talent pool of molecular natives has scientific expertise across disciplines, including therapeutic, molecular science, bioinformatics and data science. Their expertise, combined with AI and ML technologies, drives breakthrough science.
Drug discovery
Drug discovery
We accelerate drug discovery by uncovering novel aspects of disease biology to identify new targets. We help identify biomarkers and design and execute experiments, while applying in silico methods to deliver therapies to market faster.
Data and knowledge management
Data and knowledge management
We help clients advance research by using data and AI platforms for in silico science. We leverage ML, customized bioinformatics analyses and multiomics platforms to make research data accessible and actionable.
Research strategy and transformation
Research strategy and transformation
We plan and design digital transformations of research and early development—including scientific strategy, benchmarking and more—while preparing the existing organization for the change.
Precision medicine
Precision medicine
We leverage our expertise in population analytics and multiomics analysis of disease biology to deliver the right medicine to the right patient at the right time.
ZS DISCOVERY
Your cells are not alone: Why spatial omics is the next frontier of research
What’s the next frontier of understanding how to treat disease? Full 3D models of cells, organs and even organisms. To get there, we’ll need spatial transcriptomics to develop drugs based on a new understanding of how cells interact with one another. Here’s what we envision for the next omics revolution.
ZS DISCOVERY
Your cells are not alone: Why spatial omics is the next frontier of research
What’s the next frontier of understanding how to treat disease? Full 3D models of cells, organs and even organisms. To get there, we’ll need spatial transcriptomics to develop drugs based on a new understanding of how cells interact with one another. Here’s what we envision for the next omics revolution.
- A
- B
- C
- D
Connect with our experts
Connect with our experts
Insights
Insights
In the news
In the news
Related Partners
Related Partners
Databricks
From streaming analytics and AI to business intelligence, Databricks provides a modern lakehouse architecture that unifies data engineering, data science, ML and analytics within a single collaborative platform.
Seqera Labs
This partnership enables life sciences companies to scale their research environments to improve patient outcomes. ZS offers a range of services related to Seqera Labs’ technologies that help clients address a broad set of end-to-end challenges.
Velsera
This partnership aims to help innovate drug research and propel precision medicine by combining ZS’s expertise in biomedical research services and data science with Velsera’s technology platform.
ONTOFORCE
ZS and ONTOFORCE support clients in optimizing their research and development operations. We leverage use cases, omics data analysis, biomarker selection and more to offer an end-to-end service for early drug research and development.